ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Immunotherapy"

  • Abstract Number: 84 • 2019 ACR/ARP Annual Meeting

    Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome

    Estelle Gerossier 1, Saba Nayar 2, Charlotte Smith 2, Sylvie Froidevaux 3, Francesca Barone 2 and Marianne Martinic1, 1Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, 2Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, 3Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland

    Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
  • Abstract Number: 253 • 2019 ACR/ARP Annual Meeting

    A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease

    Maria Lopez-Olivo1, Noha Abdel-Wahab 1 and Maria E. Suárez-Almazor 2, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX

    Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
  • Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting

    Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis

    Elizaveta Efuni 1, Samuel Cytryn 2, Patrick Boland 2 and Sabina Sandigursky3, 1New York University School of Medicine, New York, NY, 2NYU Langone Health, New York, 3NYU Langone Health, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
  • Abstract Number: 1808 • 2019 ACR/ARP Annual Meeting

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation

    Tawnie Braaten1, Julie Brahmer 1, Patrick Forde 1, Dung Le 1, Evan Lipson 1, Jarushka Naidoo 1, Megan Schollenberger 1, Lei Zheng 1, Michelle Jones 1, Ami Shah 2, Clifton Bingham 3 and Laura Cappelli 3, 1Johns Hopkins, Baltimore, MD, 2Johns Hopkins Hospital, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD

    Background/Purpose: The use of immune checkpoint inhibitor (ICI) therapy for malignancy is growing.   Various autoimmune and inflammatory syndromes, known as immune-related adverse events (irAEs) have…
  • Abstract Number: 1956 • 2019 ACR/ARP Annual Meeting

    Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood

    Mazen Nasrallah1, Molly Thomas 2, Kasidet Manakongtreecheep 2, Daniel Zlotoff 2, Aleigha Lawless 2, Hellen Giang 2, Sara Schoenfeld 2, Ryan Sullivan 2, Genevieve Boland 2, Kerry Reynolds 2, Minna Kohler 2, Andrew Luster 2 and Alexandra-Chloé Villani 2, 1Massachusetts General Hospital, Boston, 2MGH, Boston

    Background/Purpose: Monoclonal antibodies against CTLA-4 and PD-1 have revolutionized the field of immuno-oncology over the past decade. These therapies however are limited by immune related…
  • Abstract Number: 2137 • 2019 ACR/ARP Annual Meeting

    Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma

    Michael Richter1, Jacob Orme 2, Heidi Finnes 3 and Uma Thanarajasingam 4, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, 3Department of Pharmacy, Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, MN

    Background/Purpose: The development of de novo inflammatory arthritis (IA) occurs in 2-4% of all patients with cancer treated with programmed cell death protein 1 (PD-1)…
  • Abstract Number: 2139 • 2019 ACR/ARP Annual Meeting

    Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases

    Sebastian Rodriguez-Garcia1, David Lobo 2, Fabiola Ojeda 3, Raul Castellanos-Moreira 4, Ana Laiz 2, Roberto Gumucio 4, Cesar Diaz-Torné 2, Virginia Ruiz-Esquide 5, Milena Millan 2, Ivan Castellvi 6, Patricia Moya Alvarado 7, Berta Magallares 2, Carolina Perez 3, Hector Corominas 8 and Jose Gomez-Puerta 9, 1Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, 2Rheumatology Department. Hospital Sant Pau, Barcelona, Catalonia, Spain, 3Rheumatology Department. Hospital del Mar, Barcelona, Catalonia, Spain, 4Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 5Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 8Rheumatology Department, Hospital Sant Pau, Barcelona, Catalonia, Spain, 9Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain

    Background/Purpose: Immune checkpoint inhibitors (ICI) against CTLA-4 or PD- 1/PD-L1 and more recently TIM3,  have demonstrated efficacy in improving the survival of patients with diverse…
  • Abstract Number: 2140 • 2019 ACR/ARP Annual Meeting

    Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

    Linda Laaouad1, Janet Roberts 2, Daniel Ennis 3, Carrie Ye 4, Karam Al Jumaily 5, Marie Hudson 6, Shahin Jamal 7, Janet Pope 8, Tatiana Nevskaya 9, Alexandra Saltman 10, Megan Himmel 11, Aurore Fifi-Mah 12, Annaliese Tisseverasinghe 13, Nancy Maltez 14, Ines Colmegna 15 and Sabrina Hoa 16, 1University of Montreal, Montreal, Canada, 2Dalhousie University, Halifax, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5University of Alberta, Edmonton, Canada, 6Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, 7University of British Columbia, Vancouver, BC, Canada, 8Western University, London, ON, Canada, 9University of Western Ontario, London, ON, Canada, 10University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, 11University of Toronto, Toronto, Canada, 12University of Calgary, Calgary, AB, Canada, 13University of Manitoba, Winnipeg, MB, Canada, 14University of Ottawa, Ottawa, ON, Canada, 15McGill University Health Center, Montreal, QC, Canada, 16University of Montreal, Montreal, QC, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events…
  • Abstract Number: 2146 • 2019 ACR/ARP Annual Meeting

    Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease

    Emily Carroll1, Amanda Leiter 2, Danielle Brooks 1, Jennifer Ben Shimol 3, Elliot Eisenberg 1, Matthew Galsky 4, Emily Gallagher 5 and Margrit Wiesendanger 3, 1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 2Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 3Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 4Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, 5Division of Endocrinology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies in the treatment of many cancers, but their use has been linked with immune-related adverse events (irAEs).…
  • Abstract Number: 2147 • 2019 ACR/ARP Annual Meeting

    Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events

    Mazen Nasrallah1, Sara Schoenfeld 2, Mark Matza 1, Donald Lawrence 2, Justine Cohen 2, Meghan Mooradian 2, Kerry Reynolds 2, Ryan Sullivan 2 and Minna Kohler 2, 1Massachusetts General Hospital, Boston, 2MGH, Boston

    Background/Purpose: Cancer immunotherapy with monoclonal antibodies that antagonize molecular checkpoint pathways in immune activation, the PD-1/PDL1 axis and CTLA-4, have revolutionized the treatment of solid…
  • Abstract Number: 2157 • 2019 ACR/ARP Annual Meeting

    Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival

    Karmela Kim Chan 1, Aidan Tirpack 1, Caroline Benson 1, Gregory Vitone 1, Jackie Finik 2, Vivian Bykerk 3, Susan Goodman 4, Laura Donlin 5, Deepak Rao 6 and Anne Bass4, 1Hospital For Special Surgery, New York, 2Hospital for Special Surgery, New York, NY, New York, NY, 3Hospital for Special Surgery, New York City, NY, 4Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, 5Hospital For Special Surgery, New York, NY, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Previous studies suggest that steroid dose1and rheumatoid factor positivity2 impact cancer survival in checkpoint inhibitor (CI)-treated patients (with CI-associated hypophysitis, and in all-comers with non-small…
  • Abstract Number: 2158 • 2019 ACR/ARP Annual Meeting

    Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)

    Janet Roberts1, Daniel Ennis 2, Marie Hudson 3, Carrie Ye 4, Alexandra Saltman 5, Sabrina Hoa 6, Janet Pope 7, Megan Himmel 2, Nancy Maltez 8, Aurore Fifi-Mah 9, Annaliese Tisseverasinghe 10, Robert Rottapel 11, Karam Al Jumaily 12, Christina Ly 13, Liliana Cartagena 14 and Shahin Jamal 15, 1Dalhousie University, Halifax, NS, Canada, 2University of Toronto, Toronto, ON, Canada, 3Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, 6University of Montreal, Montreal, QC, Canada, 7Western University, London, ON, Canada, 8University of Ottawa, Ottawa, ON, Canada, 9University of Calgary, Calgary, AB, Canada, 10University of Manitoba, Winnipeg, MB, Canada, 11University of Toronto, Toronto, Canada, 12University of Alberta, edmonton, Canada, 13McGill University, Montreal, Canada, 14Arthritis Research Canada, Vancouver, Canada, 15University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by harnessing the immune system to fight cancer.  They are associated with the development of autoimmune…
  • Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting

    Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE

    Jens Humrich1, Caroline von Spee-Mayer2, Philipp Enghard3, Angelika Rose4, Elise Siegert5, Tobias Alexander5, Falk Hiepe6, Gerd R. Burmester7 and Gabriela Riemekasten8, 1Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, 2Immunology, University Hospital Freiburg, Freiburg, Germany, 3Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, 4Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 5Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 6Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, 7Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 8Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany

    Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
  • Abstract Number: 346 • 2018 ACR/ARHP Annual Meeting

    Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care

    Pankti Reid1 and Reem Jan2, 1Internal Medicine, rheumatology, University of Chicago, Chicago, IL, 2Medicine, Rheumatology, University of Chicago, Chicago, IL

    Background/Purpose: The growing use of cancer immunotherapy and checkpoint inhibitors has led to a steep rise in immune-related adverse events (irAEs). Despite expanding research efforts,…
  • Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting

    Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis

    Celine Anquetil1,2, Joe-Elie Salem3,4, Benedicte Lebrun-Vignes5, Douglas B Johnson6, Andrew Mammen7,8, Werner Stenzel9, Sarah Leonard-louis10, Olivier Benveniste11,12, Javid J Moslehi3 and Yves Allenbach2,13, 1Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, 2CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, 3Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, 4Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, 5Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, 6Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 8Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 9Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, 10Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, 11Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, 12Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, 13Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France

    Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology